{Reference Type}: Journal Article
{Title}: Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
{Author}: Verkerk K;Otten HM;Huitema ADR;
{Journal}: Cancer Chemother Pharmacol
{Volume}: 0
{Issue}: 0
{Year}: Sep 2022 20
{Factor}: 3.288
{DOI}: 10.1007/s00280-022-04476-6
{Abstract}: Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.